MX2020004455A - Derivados de pirrolopirazina como inhibidores de integrina alfa v. - Google Patents

Derivados de pirrolopirazina como inhibidores de integrina alfa v.

Info

Publication number
MX2020004455A
MX2020004455A MX2020004455A MX2020004455A MX2020004455A MX 2020004455 A MX2020004455 A MX 2020004455A MX 2020004455 A MX2020004455 A MX 2020004455A MX 2020004455 A MX2020004455 A MX 2020004455A MX 2020004455 A MX2020004455 A MX 2020004455A
Authority
MX
Mexico
Prior art keywords
alpha
integrin inhibitors
pyrrolopyrazine derivatives
pyrrolopyrazine
derivatives
Prior art date
Application number
MX2020004455A
Other languages
English (en)
Inventor
Guohua Zhao
James Mignone
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2020004455A publication Critical patent/MX2020004455A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula I: (Ver fórmula I), los cuales inhiben las integrinas que contienen a?, e incluyen composiciones farmacéuticas que comprenden estos compuestos y métodos para tratar una enfermedad, trastorno, o condición asociada con la disregulación de integrinas que contienen aV, tales como fibrosis patológicas, rechazo al transplante, cáncer, osteoporosis, y trastornos inflamatorios.
MX2020004455A 2017-11-07 2018-11-05 Derivados de pirrolopirazina como inhibidores de integrina alfa v. MX2020004455A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762582693P 2017-11-07 2017-11-07
PCT/US2018/059157 WO2019094319A1 (en) 2017-11-07 2018-11-05 Pyrrolopyrazine derivatives as alpha v integrin inhibitors

Publications (1)

Publication Number Publication Date
MX2020004455A true MX2020004455A (es) 2020-07-24

Family

ID=64362756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004455A MX2020004455A (es) 2017-11-07 2018-11-05 Derivados de pirrolopirazina como inhibidores de integrina alfa v.

Country Status (14)

Country Link
US (1) US11292802B2 (es)
EP (1) EP3707142B1 (es)
JP (1) JP7291696B2 (es)
KR (1) KR102700471B1 (es)
CN (1) CN111433207B (es)
AU (1) AU2018365793A1 (es)
BR (1) BR112020008893A2 (es)
CA (1) CA3081805A1 (es)
EA (1) EA202091136A1 (es)
ES (1) ES2904645T3 (es)
IL (1) IL274425A (es)
MX (1) MX2020004455A (es)
SG (1) SG11202004077WA (es)
WO (1) WO2019094319A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7291696B2 (ja) * 2017-11-07 2023-06-15 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのピロロピラジン誘導体
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4076454A1 (en) * 2019-12-20 2022-10-26 Novartis AG Combination treatment of liver diseases using integrin inhibitors
WO2026037432A1 (zh) * 2024-08-16 2026-02-19 中研眼健康服务常州有限公司 一种取代的吡啶类化合物及其制备方法、其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
JP2001524481A (ja) 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
EP1047425A4 (en) 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
AU748621B2 (en) 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
JP2004521079A (ja) * 2000-08-29 2004-07-15 ファルマシア・コーポレーション アルファーｖベータ３アンタゴニストとして有用な二環式環系を含有する化合物
WO2002060438A1 (en) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
BR0317600A (pt) * 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
US7365209B2 (en) * 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
WO2006108040A1 (en) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
JP2009539815A (ja) 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
JP2011184298A (ja) 2008-06-02 2011-09-22 Sanwa Kagaku Kenkyusho Co Ltd 新規化合物及びその医薬用途
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
JP7291696B2 (ja) * 2017-11-07 2023-06-15 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのピロロピラジン誘導体

Also Published As

Publication number Publication date
KR20200084879A (ko) 2020-07-13
WO2019094319A1 (en) 2019-05-16
EP3707142A1 (en) 2020-09-16
US11292802B2 (en) 2022-04-05
JP2021502358A (ja) 2021-01-28
BR112020008893A2 (pt) 2020-10-13
JP7291696B2 (ja) 2023-06-15
CA3081805A1 (en) 2019-05-16
SG11202004077WA (en) 2020-05-28
EP3707142B1 (en) 2021-12-08
IL274425A (en) 2020-06-30
US20210163501A1 (en) 2021-06-03
ES2904645T3 (es) 2022-04-05
KR102700471B1 (ko) 2024-08-28
CN111433207A (zh) 2020-07-17
EA202091136A1 (ru) 2020-07-29
AU2018365793A1 (en) 2020-06-18
CN111433207B (zh) 2023-07-25

Similar Documents

Publication Publication Date Title
MX2020003430A (es) Derivados de 1-bencil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de proteasa de virus de inmunodeficiencia humana.
MX2020004287A (es) Procesamiento de biomasa.
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
MX2020003760A (es) Formulaciones de niraparib.
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
MX2020004708A (es) Sistema y metodos de transporte.
HRP20240375T8 (hr) Derivati aminopirimidina kao inhibitori ctps1
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
IL274425A (en) Pyrrolopyrazine derivatives as alpha five integrin inhibitors
MX2020004424A (es) Formulacion aerosolizable.
MX2017001981A (es) Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1).
MX2020004071A (es) Derivados de aztreonam y usos de los mismos.
MX2020003439A (es) Compuestos biciclicos para usarse como inhibidores de cinasa de la proteina 1 de interaccion con receptores (rip1).
MX2020003440A (es) Red de seguridad.
MY165760A (en) Absorbent article
CA192893S (en) Bottle
MX2019015167A (es) Farmacos antivirales.
MX2020004662A (es) Ajuste planificado del contorno mediante especificaciones correspondientes.
MX2020003616A (es) Nuevo derivado de fenilpiridina y composicion farmaceutica que lo contiene.
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
MX2020004008A (es) Caja de carton y plantilla para la misma.
MX2020002908A (es) Composicion acuosa de polimeros.
MX2020003611A (es) Metodos de refuerzo del pozo.
MX2020003487A (es) Compuestos inhibidores de pirimidina tbk/ikkepsilon y usos de los mismos.
MX2020003703A (es) Composiciones de sabor.